An RNA Mapping Strategy to Identify Ribozyme-Accessible Sites on the Catalytic Subunit of Mouse TelomeraseTelomerase reverse transcriptase (TERT) is an enzymatic ribonucleoprotein that prolongs the replicative life span of cells by maintaining protective structures at the ends of eukaryotic chromosomes.
('An', 'An', 'DT', 'B-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('Mapping', 'Mapping', 'NN', 'I-NP', 'O')
('Strategy', 'Strategy', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('Identify', 'Identify', 'VB', 'I-VP', 'O')
('Ribozyme-Accessible', 'Ribozyme-Accessible', 'JJ', 'B-NP', 'B-DNA')
('Sites', 'Site', 'NNS', 'I-NP', 'I-DNA')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Catalytic', 'Catalytic', 'JJ', 'I-NP', 'B-protein')
('Subunit', 'Subunit', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('Mouse', 'Mouse', 'NN', 'B-NP', 'O')
('Telomerase', 'Telomerase', 'NN', 'I-NP', 'O')
('Telomerase', 'Telomerase', 'NN', 'I-NP', 'O')
('reverse', 'reverse', 'JJ', 'I-NP', 'O')
('transcriptase', 'transcriptase', 'NN', 'I-NP', 'O')
('(TERT)', '(TERT)', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('enzymatic', 'enzymatic', 'JJ', 'I-NP', 'O')
('ribonucleoprotein', 'ribonucleoprotein', 'NN', 'I-NP', 'B-protein')
('that', 'that', 'WDT', 'B-NP', 'O')
('prolongs', 'prolong', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('replicative', 'replicative', 'JJ', 'I-NP', 'O')
('life', 'life', 'NN', 'I-NP', 'O')
('span', 'span', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('cells', 'cell', 'NNS', 'B-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('maintaining', 'maintain', 'VBG', 'B-VP', 'O')
('protective', 'protective', 'JJ', 'B-NP', 'O')
('structures', 'structure', 'NNS', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ends', 'end', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('eukaryotic', 'eukaryotic', 'JJ', 'B-NP', 'O')
('chromosomes.', 'chromosomes.', 'NNS', 'I-NP', 'O')
Telomerase activity is highly up-regulated in 85-90% of human cancers, and is predominately regulated by hTERT expression.
('Telomerase', 'Telomerase', 'NN', 'B-NP', 'B-protein')
('activity', 'activity', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('highly', 'highly', 'RB', 'I-VP', 'O')
('up-regulated', 'up-regulate', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('85-90%', '85-90%', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'O')
('cancers,', 'cancers,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('predominately', 'predominately', 'RB', 'I-VP', 'O')
('regulated', 'regulate', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('hTERT', 'hTERT', 'NN', 'B-NP', 'O')
('expression.', 'expression.', 'NN', 'I-NP', 'O')
In contrast, most normal somatic tissues in humans express low or undetectable levels of telomerase activity.
('In', 'In', 'IN', 'B-PP', 'O')
('contrast,', 'contrast,', 'NN', 'B-NP', 'O')
('most', 'most', 'RBS', 'B-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('somatic', 'somatic', 'JJ', 'I-NP', 'O')
('tissues', 'tissue', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('humans', 'human', 'NNS', 'B-NP', 'O')
('express', 'express', 'VBP', 'B-VP', 'O')
('low', 'low', 'JJ', 'B-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('undetectable', 'undetectable', 'JJ', 'I-NP', 'O')
('levels', 'level', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('telomerase', 'telomerase', 'NN', 'B-NP', 'O')
('activity.', 'activity.', 'NN', 'I-NP', 'O')
This expression profile identifies TERT as a potential anti cancer target.
('This', 'This', 'DT', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('profile', 'profile', 'NN', 'I-NP', 'O')
('identifies', 'identify', 'VBZ', 'B-VP', 'O')
('TERT', 'TERT', 'NN', 'B-NP', 'B-protein')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('potential', 'potential', 'JJ', 'I-NP', 'O')
('anti', 'anti', 'JJ', 'I-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('target.', 'target.', 'NN', 'I-NP', 'O')
By using an RNA mapping strategy based on a frans-splicing ribozyme library, we identified the regions of mouse TERT (mTERT) RNA that were accessible to ribozymes.
('By', 'By', 'IN', 'B-PP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('mapping', 'mapping', 'NN', 'I-NP', 'O')
('strategy', 'strategy', 'NN', 'I-NP', 'O')
('based', 'base', 'VBN', 'B-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('frans-splicing', 'frans-splicing', 'JJ', 'I-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('library,', 'library,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('identified', 'identify', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('regions', 'region', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('mouse', 'mouse', 'NN', 'B-NP', 'B-RNA')
('TERT', 'TERT', 'NN', 'I-NP', 'I-RNA')
('(mTERT)', '(mTERT)', 'NN', 'I-NP', 'I-RNA')
('RNA', 'RNA', 'NN', 'I-NP', 'I-RNA')
('that', 'that', 'WDT', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('accessible', 'accessible', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('ribozymes.', 'ribozymes.', 'VB', 'I-VP', 'O')
We found that particularly accessible sites were present downstream of the AUG start codon.
('We', 'We', 'PRP', 'B-NP', 'O')
('found', 'find', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('particularly', 'particularly', 'RB', 'B-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'O')
('sites', 'site', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('present', 'present', 'JJ', 'B-ADJP', 'O')
('downstream', 'downstream', 'RB', 'B-ADVP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('AUG', 'AUG', 'NN', 'I-NP', 'O')
('start', 'start', 'NN', 'I-NP', 'O')
('codon.', 'codon.', 'NN', 'I-NP', 'O')
This mTERT- specific ribozyme will be useful for validation of the RNA replacement as cancer gene therapy approach in mouse model with syngeneic tumors.
('This', 'This', 'DT', 'B-NP', 'O')
('mTERT-', 'mTERT-', 'NN', 'I-NP', 'O')
('specific', 'specific', 'JJ', 'I-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('will', 'will', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('useful', 'useful', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('validation', 'validation', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('replacement', 'replacement', 'NN', 'I-NP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('cancer', 'cancer', 'NN', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('therapy', 'therapy', 'NN', 'I-NP', 'O')
('approach', 'approach', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('mouse', 'mouse', 'NN', 'B-NP', 'O')
('model', 'model', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('syngeneic', 'syngeneic', 'JJ', 'B-NP', 'O')
('tumors.', 'tumors.', 'NNS', 'I-NP', 'O')
A comparison with normal somatic tissues has shown that telomerase activity is up-regulated in the vast majority of human tumors.
('A', 'A', 'DT', 'B-NP', 'O')
('comparison', 'comparison', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('normal', 'normal', 'JJ', 'B-NP', 'O')
('somatic', 'somatic', 'JJ', 'I-NP', 'O')
('tissues', 'tissue', 'NNS', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('telomerase', 'telomerase', 'NN', 'B-NP', 'B-protein')
('activity', 'activity', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('up-regulated', 'up-regulate', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('vast', 'vast', 'JJ', 'I-NP', 'O')
('majority', 'majority', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'O')
('tumors.', 'tumors.', 'NNS', 'I-NP', 'O')
Particularly, expression of the catalytic subunit of telomerase, TERT, in cultured human primary cells reconstitutes telomerase activity and facilitates immortal cell growth (Bodnareta/., 1998).
('Particularly,', 'Particularly,', 'NN', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('catalytic', 'catalytic', 'JJ', 'I-NP', 'B-protein')
('subunit', 'subunit', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('telomerase,', 'telomerase,', 'NN', 'B-NP', 'B-protein')
('TERT,', 'TERT,', 'NN', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('cultured', 'culture', 'VBN', 'B-NP', 'B-cell_line')
('human', 'human', 'JJ', 'I-NP', 'I-cell_line')
('primary', 'primary', 'JJ', 'I-NP', 'I-cell_line')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_line')
('reconstitutes', 'reconstitute', 'VBZ', 'B-VP', 'O')
('telomerase', 'telomerase', 'NN', 'B-NP', 'B-protein')
('activity', 'activity', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('facilitates', 'facilitate', 'VBZ', 'B-VP', 'O')
('immortal', 'immortal', 'JJ', 'B-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('growth', 'growth', 'NN', 'I-NP', 'O')
('(Bodnareta/.,', '(Bodnareta/.,', 'NN', 'I-NP', 'O')
('1998).', '1998).', 'CD', 'I-NP', 'O')
Furthermore, TERT-driven cell proliferation results in the activation of the c-myc oncogene (Wang et al., 2000), and TERT- activated telomerase can cooperate with other oncogenes to transform primary human cultured cells into neoplastic cells (Hahn etal., 1999).
('Furthermore,', 'Furthermore,', 'RB', 'B-NP', 'O')
('TERT-driven', 'TERT-driven', 'JJ', 'I-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('proliferation', 'proliferation', 'NN', 'I-NP', 'O')
('results', 'result', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('activation', 'activation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('c-myc', 'c-myc', 'NN', 'I-NP', 'B-DNA')
('oncogene', 'oncogene', 'NN', 'I-NP', 'I-DNA')
('(Wang', '(Wang', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2000),', '2000),', 'CD', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('TERT-', 'TERT-', 'NN', 'B-NP', 'B-protein')
('activated', 'activate', 'VBD', 'B-VP', 'I-protein')
('telomerase', 'telomerase', 'NN', 'B-NP', 'I-protein')
('can', 'can', 'MD', 'B-VP', 'O')
('cooperate', 'cooperate', 'VB', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('oncogenes', 'oncogene', 'NNS', 'I-NP', 'B-DNA')
('to', 'to', 'TO', 'B-VP', 'O')
('transform', 'transform', 'VB', 'I-VP', 'O')
('primary', 'primary', 'JJ', 'B-NP', 'B-cell_type')
('human', 'human', 'JJ', 'I-NP', 'I-cell_type')
('cultured', 'culture', 'VBN', 'I-NP', 'I-cell_type')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_type')
('into', 'into', 'IN', 'B-PP', 'O')
('neoplastic', 'neoplastic', 'JJ', 'B-NP', 'B-cell_type')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_type')
('(Hahn', '(Hahn', 'NNP', 'B-NP', 'O')
('etal.,', 'etal.,', 'VBD', 'B-VP', 'O')
('1999).', '1999).', 'CD', 'B-NP', 'O')
The effects observed in cultured cells suggested that telomerase upregulation, which occurs in >90% of all human tumors (reviewed in Shay and Bacchetti, 1997), may actively contribute to tumor growth(reviewed in Weitzman and Yaniv, 1999).
('The', 'The', 'DT', 'B-NP', 'O')
('effects', 'effect', 'NNS', 'I-NP', 'O')
('observed', 'observe', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('cultured', 'culture', 'VBN', 'B-NP', 'B-cell_line')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_line')
('suggested', 'suggest', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('telomerase', 'telomerase', 'NN', 'B-NP', 'O')
('upregulation,', 'upregulation,', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('occurs', 'occur', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('>90%', '>90%', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('all', 'all', 'DT', 'B-NP', 'O')
('human', 'human', 'JJ', 'I-NP', 'O')
('tumors', 'tumor', 'NNS', 'I-NP', 'O')
('(reviewed', '(reviewe', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Shay', 'Shay', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Bacchetti,', 'Bacchetti,', 'NNP', 'B-NP', 'O')
('1997),', '1997),', 'CD', 'I-NP', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('actively', 'actively', 'RB', 'I-VP', 'O')
('contribute', 'contribute', 'VB', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('tumor', 'tumor', 'NN', 'B-NP', 'O')
('growth', 'growth', 'NN', 'I-NP', 'O')
('(reviewed', '(reviewe', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Weitzman', 'Weitzman', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Yaniv,', 'Yaniv,', 'NNP', 'B-NP', 'O')
('1999).', '1999).', 'CD', 'I-NP', 'O')
Therefore, telomerase activity inhibition in tumor cells has been proposed as a potential approach for cancer therapy.
('Therefore,', 'Therefore,', 'NN', 'B-NP', 'O')
('telomerase', 'telomerase', 'NN', 'I-NP', 'O')
('activity', 'activity', 'NN', 'I-NP', 'O')
('inhibition', 'inhibition', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('tumor', 'tumor', 'NN', 'B-NP', 'B-cell_type')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_type')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('proposed', 'propose', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('potential', 'potential', 'JJ', 'I-NP', 'O')
('approach', 'approach', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('cancer', 'cancer', 'NN', 'B-NP', 'O')
('therapy.', 'therapy.', '.', 'O', 'O')
Recently, we described a new approach to human cancer gene therapy that relies on the Tetrahymena group l-based tra ns-s pl icing ribozyme.
('Recently,', 'Recently,', 'NN', 'B-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('described', 'describe', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('new', 'new', 'JJ', 'I-NP', 'O')
('approach', 'approach', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'B-DNA')
('cancer', 'cancer', 'NN', 'I-NP', 'I-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('therapy', 'therapy', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('relies', 'rely', 'VBZ', 'B-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Tetrahymena', 'Tetrahymena', 'NNP', 'I-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('l-based', 'l-based', 'JJ', 'I-NP', 'O')
('tra', 'tra', 'NN', 'I-NP', 'O')
('ns-s', 'ns-', 'NNS', 'I-NP', 'O')
('pl', 'pl', 'NN', 'I-NP', 'O')
('icing', 'icing', 'NN', 'I-NP', 'O')
('ribozyme.', 'ribozyme.', 'NN', 'I-NP', 'O')
This ribozyme can specifically mediate RNA replacement of human TERT (hTERT) RNAs with new transcripts that exert cytotoxic effects, orcause up-regulation of suicide gene activity in the hTERT RNA-expressing cancer cells.
('This', 'This', 'DT', 'B-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'B-protein')
('can', 'can', 'MD', 'B-VP', 'O')
('specifically', 'specifically', 'RB', 'I-VP', 'O')
('mediate', 'mediate', 'VB', 'I-VP', 'O')
('RNA', 'RNA', 'NN', 'B-NP', 'O')
('replacement', 'replacement', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'B-RNA')
('TERT', 'TERT', 'NN', 'I-NP', 'I-RNA')
('(hTERT)', '(hTERT)', 'NN', 'I-NP', 'I-RNA')
('RNAs', 'RNA', 'NNS', 'I-NP', 'I-RNA')
('with', 'with', 'IN', 'B-PP', 'O')
('new', 'new', 'JJ', 'B-NP', 'O')
('transcripts', 'transcript', 'NNS', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('exert', 'exert', 'VBP', 'B-VP', 'O')
('cytotoxic', 'cytotoxic', 'JJ', 'B-NP', 'O')
('effects,', 'effects,', 'NN', 'I-NP', 'O')
('orcause', 'orcause', 'NN', 'I-NP', 'O')
('up-regulation', 'up-regulation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('suicide', 'suicide', 'NN', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('activity', 'activity', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('hTERT', 'hTERT', 'NN', 'I-NP', 'O')
('RNA-expressing', 'RNA-expressing', 'JJ', 'I-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('cells.', 'cells.', 'NNS', 'I-NP', 'O')
These attributes enable the ribozyme to selectively impede the growth of telomerase-positive human cancer cells in cell cultures, and in xenotransplants in mice (Kwon et al., 2005).
('These', 'These', 'DT', 'B-NP', 'O')
('attributes', 'attribute', 'NNS', 'I-NP', 'O')
('enable', 'enable', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('selectively', 'selectively', 'RB', 'I-VP', 'O')
('impede', 'impede', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('growth', 'growth', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('telomerase-positive', 'telomerase-positive', 'JJ', 'B-NP', 'B-cell_type')
('human', 'human', 'JJ', 'I-NP', 'I-cell_type')
('cancer', 'cancer', 'NN', 'I-NP', 'I-cell_type')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_type')
('in', 'in', 'IN', 'B-PP', 'O')
('cell', 'cell', 'NN', 'B-NP', 'O')
('cultures,', 'cultures,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'B-PP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('xenotransplants', 'xenotransplant', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('mice', 'mouse', 'NNS', 'B-NP', 'O')
('(Kwon', '(Kwon', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
Apreclinical index which includes therapeutic effects, toxicities, and pharmacokinetics must be determined to evaluate the therapeutic potential of the hTERT-specific ribozyme in a clinical setting.
('Apreclinical', 'Apreclinical', 'JJ', 'B-NP', 'O')
('index', 'index', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('includes', 'include', 'VBZ', 'B-VP', 'O')
('therapeutic', 'therapeutic', 'JJ', 'B-NP', 'O')
('effects,', 'effects,', 'NN', 'I-NP', 'O')
('toxicities,', 'toxicities,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('pharmacokinetics', 'pharmacokinetic', 'NNS', 'I-NP', 'O')
('must', 'must', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('determined', 'determine', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('evaluate', 'evaluate', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('therapeutic', 'therapeutic', 'JJ', 'I-NP', 'O')
('potential', 'potential', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('hTERT-specific', 'hTERT-specific', 'JJ', 'I-NP', 'B-protein')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('clinical', 'clinical', 'JJ', 'I-NP', 'O')
('setting.', 'setting.', 'NN', 'I-NP', 'O')
An established animal model with syngeneic tumors would be useful in evaluating the ribozyme using standard immunological surveillance methods (Shi et al., 2001).
('An', 'An', 'DT', 'B-NP', 'O')
('established', 'established', 'JJ', 'I-NP', 'O')
('animal', 'animal', 'NN', 'I-NP', 'O')
('model', 'model', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('syngeneic', 'syngeneic', 'JJ', 'B-NP', 'O')
('tumors', 'tumor', 'NNS', 'I-NP', 'O')
('would', 'would', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('useful', 'useful', 'JJ', 'B-ADJP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('evaluating', 'evaluate', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'B-protein')
('using', 'use', 'VBG', 'B-VP', 'O')
('standard', 'standard', 'JJ', 'B-NP', 'O')
('immunological', 'immunological', 'JJ', 'I-NP', 'O')
('surveillance', 'surveillance', 'NN', 'I-NP', 'O')
('methods', 'method', 'NNS', 'I-NP', 'O')
('(Shi', '(Shi', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2001).', '2001).', 'CD', 'B-NP', 'O')
To this end, we have developed mouse TERT (mTERT)-specific trans- splicing ribozymes by utilizing an RNA mapping method that identifies the most accessible ribozyme sites.
('To', 'To', 'TO', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('end,', 'end,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('developed', 'develop', 'VBN', 'I-VP', 'O')
('mouse', 'mouse', 'NN', 'B-NP', 'B-protein')
('TERT', 'TERT', 'NN', 'I-NP', 'I-protein')
('(mTERT)-specific', '(mTERT)-specific', 'JJ', 'I-NP', 'I-protein')
('trans-', 'trans-', 'NN', 'I-NP', 'I-protein')
('splicing', 'splicing', 'NN', 'I-NP', 'I-protein')
('ribozymes', 'ribozyme', 'NNS', 'I-NP', 'I-protein')
('by', 'by', 'IN', 'B-PP', 'O')
('utilizing', 'utilize', 'VBG', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('mapping', 'mapping', 'NN', 'I-NP', 'O')
('method', 'method', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('identifies', 'identify', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('most', 'most', 'RBS', 'I-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('sites.', 'sites.', 'NNS', 'I-NP', 'O')
There is considerable flexibility in the selection of specific sites in target RNA for the frans-splicing ribozyme.
('There', 'There', 'EX', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('considerable', 'considerable', 'JJ', 'B-NP', 'O')
('flexibility', 'flexibility', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('selection', 'selection', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('specific', 'specific', 'JJ', 'B-NP', 'O')
('sites', 'site', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('target', 'target', 'NN', 'B-NP', 'B-RNA')
('RNA', 'RNA', 'NN', 'I-NP', 'I-RNA')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('frans-splicing', 'frans-splicing', 'NN', 'I-NP', 'O')
('ribozyme.', 'ribozyme.', 'NN', 'I-NP', 'O')
This is because virtually any uridine (U) residue in a 5’exon can be targeted for splicing by altering the nucleotide composition of the 5’ exon binding site on the ribozyme.
('This', 'This', 'DT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('because', 'because', 'IN', 'B-SBAR', 'O')
('virtually', 'virtually', 'RB', 'B-NP', 'O')
('any', 'any', 'DT', 'I-NP', 'O')
('uridine', 'uridine', 'NN', 'I-NP', 'O')
('(U)', '(U)', 'NN', 'I-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('5’exon', '5’exon', 'NN', 'I-NP', 'B-DNA')
('can', 'can', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('targeted', 'target', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('splicing', 'splicing', 'NN', 'B-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('altering', 'alter', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('composition', 'composition', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('5’', '5’', 'CD', 'I-NP', 'B-DNA')
('exon', 'exon', 'NN', 'I-NP', 'I-DNA')
('binding', 'binding', 'NN', 'I-NP', 'I-DNA')
('site', 'site', 'NN', 'I-NP', 'I-DNA')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ribozyme.', 'ribozyme.', 'NN', 'I-NP', 'O')
This region is called the internal guide sequence (IGS), and it can be altered to make it complementary to a target sequence that is present on the substrate RNA (Sullenger, 1995; Long etal., 2003).
('This', 'This', 'DT', 'B-NP', 'O')
('region', 'region', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('called', 'call', 'VBN', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('internal', 'internal', 'JJ', 'I-NP', 'O')
('guide', 'guide', 'NN', 'I-NP', 'O')
('sequence', 'sequence', 'NN', 'I-NP', 'O')
('(IGS),', '(IGS),', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('it', 'it', 'PRP', 'B-NP', 'O')
('can', 'can', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('altered', 'alter', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('make', 'make', 'VB', 'I-VP', 'O')
('it', 'it', 'PRP', 'B-NP', 'O')
('complementary', 'complementary', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'B-DNA')
('sequence', 'sequence', 'NN', 'I-NP', 'I-DNA')
('that', 'that', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('present', 'present', 'JJ', 'B-ADJP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('substrate', 'substrate', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('(Sullenger,', '(Sullenger,', 'NN', 'I-NP', 'O')
('1995;', '1995;', 'CD', 'I-NP', 'O')
('Long', 'Long', 'NNP', 'I-NP', 'O')
('etal.,', 'etal.,', 'NN', 'I-NP', 'O')
('2003).', '2003).', 'CD', 'I-NP', 'O')
However, only a limited number of uridines on the target RNA may actually be accessible to the ribozyme due to the complex, but stable tertiary configuration of the substrate RNA (Lan et al., 2000).
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('only', 'only', 'RB', 'B-NP', 'O')
('a', 'a', 'DT', 'I-NP', 'O')
('limited', 'limit', 'VBN', 'I-NP', 'O')
('number', 'number', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('uridines', 'uridine', 'NNS', 'B-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('actually', 'actually', 'RB', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('accessible', 'accessible', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('due', 'due', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('complex,', 'complex,', 'NN', 'I-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('stable', 'stable', 'JJ', 'B-NP', 'O')
('tertiary', 'tertiary', 'JJ', 'I-NP', 'O')
('configuration', 'configuration', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('substrate', 'substrate', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('(Lan', '(Lan', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2000).', '2000).', 'CD', 'B-NP', 'O')
Therefore, an RNA mapping strategy was performed to identify regions of the mTERT transcript that were accessible to ribozymes.
('Therefore,', 'Therefore,', 'RB', 'B-ADVP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('mapping', 'mapping', 'NN', 'I-NP', 'O')
('strategy', 'strategy', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('performed', 'perform', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('regions', 'region', 'NNS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'B-RNA')
('transcript', 'transcript', 'NN', 'I-NP', 'I-RNA')
('that', 'that', 'WDT', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('accessible', 'accessible', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('ribozymes.', 'ribozymes.', 'VB', 'I-VP', 'O')
The applied mapping methodology relied on RNA tagging (Jones et al., 1996) and a frans-splicing ribozyme library which has been described in detail elsewhere (Fig.
('The', 'The', 'DT', 'B-NP', 'O')
('applied', 'apply', 'VBN', 'I-NP', 'O')
('mapping', 'mapping', 'NN', 'I-NP', 'O')
('methodology', 'methodology', 'NN', 'I-NP', 'O')
('relied', 'rely', 'VBN', 'B-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('RNA', 'RNA', 'NN', 'B-NP', 'O')
('tagging', 'tag', 'VBG', 'B-VP', 'O')
('(Jones', '(Jone', 'NNS', 'B-NP', 'B-protein')
('et', 'et', 'FW', 'B-NP', 'I-protein')
('al.,', 'al.,', 'FW', 'I-NP', 'I-protein')
('1996)', '1996)', 'CD', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('frans-splicing', 'frans-splicing', 'JJ', 'I-NP', 'B-DNA')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'I-DNA')
('library', 'library', 'NN', 'I-NP', 'I-DNA')
('which', 'which', 'WDT', 'B-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('described', 'describe', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('detail', 'detail', 'NN', 'B-NP', 'O')
('elsewhere', 'elsewhere', 'RB', 'B-ADVP', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
1)(Lan etal., 1998; Lan etal., 2000; Ryu et al., 2003).
('1)(Lan', '1)(Lan', 'NN', 'B-NP', 'O')
('etal.,', 'etal.,', ',', 'O', 'O')
('1998;', '1998;', 'CD', 'B-NP', 'O')
('Lan', 'Lan', 'NNP', 'I-NP', 'O')
('etal.,', 'etal.,', 'NNP', 'I-NP', 'O')
('2000;', '2000;', ':', 'O', 'O')
('Ryu', 'Ryu', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
The construction of the GN5 ribozyme library used in this study was based on the Tetrahymena group I intron and contains a randomized IGS.
('The', 'The', 'DT', 'B-NP', 'O')
('construction', 'construction', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('GN5', 'GN5', 'NN', 'I-NP', 'B-DNA')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'I-DNA')
('library', 'library', 'NN', 'I-NP', 'I-DNA')
('used', 'use', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('based', 'base', 'VBN', 'I-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Tetrahymena', 'Tetrahymena', 'NNP', 'I-NP', 'B-DNA')
('group', 'group', 'NN', 'I-NP', 'I-DNA')
('I', 'I', 'CD', 'I-NP', 'I-DNA')
('intron', 'intron', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('contains', 'contain', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('randomized', 'randomize', 'VBN', 'I-NP', 'O')
('IGS.', 'IGS.', 'NNP', 'I-NP', 'O')
Ribozymes in the GN5 library can bind to the substrate RNA and cleave at any accessible U residue, followed by the transference of a 3’ exon to the end of the 5’ target cleavage product.
('Ribozymes', 'Ribozyme', 'NNS', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('GN5', 'GN5', 'NN', 'I-NP', 'B-DNA')
('library', 'library', 'NN', 'I-NP', 'I-DNA')
('can', 'can', 'MD', 'B-VP', 'O')
('bind', 'bind', 'VB', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('substrate', 'substrate', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('cleave', 'cleave', 'VBP', 'B-VP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('any', 'any', 'DT', 'B-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'O')
('U', 'U', 'NN', 'I-NP', 'O')
('residue,', 'residue,', 'NN', 'I-NP', 'O')
('followed', 'follow', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('transference', 'transference', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('3’', '3’', 'NN', 'I-NP', 'B-DNA')
('exon', 'exon', 'NN', 'I-NP', 'I-DNA')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('end', 'end', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('5’', '5’', 'CD', 'I-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'O')
('cleavage', 'cleavage', 'NN', 'I-NP', 'O')
('product.', 'product.', 'NN', 'I-NP', 'O')
Part of the lacZ gene was used as a 3’ exon molecular tag in the GN5 library that could be spliced onto the accessible target RNA’s.
('Part', 'Part', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('lacZ', 'lacZ', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('3’', '3’', 'NN', 'I-NP', 'B-DNA')
('exon', 'exon', 'NN', 'I-NP', 'I-DNA')
('molecular', 'molecular', 'JJ', 'I-NP', 'I-DNA')
('tag', 'tag', 'NN', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('GN5', 'GN5', 'NN', 'I-NP', 'B-DNA')
('library', 'library', 'NN', 'I-NP', 'I-DNA')
('that', 'that', 'WDT', 'B-NP', 'O')
('could', 'could', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('spliced', 'splice', 'VBN', 'I-VP', 'O')
('onto', 'onto', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'O')
('RNA’s.', 'RNA’s.', 'NN', 'I-NP', 'O')
In orderto map the mTERT RNA, 10 nM ofthe GN5 library was incubated at 37°C for 3 h under splicing conditions (50 mM HEPES, pH 7.0,150 mM NaCI, 5 mM MgCb) in the presence of guanosine (200 pM) and 100 nM of in vitro generated mTERT RNA.
('In', 'In', 'IN', 'B-PP', 'O')
('orderto', 'orderto', 'NN', 'B-NP', 'O')
('map', 'map', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'B-DNA')
('RNA,', 'RNA,', 'NN', 'I-NP', 'I-DNA')
('10', '10', 'CD', 'I-NP', 'I-DNA')
('nM', 'nM', 'NN', 'I-NP', 'I-DNA')
('ofthe', 'ofthe', 'IN', 'B-PP', 'I-DNA')
('GN5', 'GN5', 'NN', 'B-NP', 'I-DNA')
('library', 'library', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('incubated', 'incubate', 'VBN', 'I-VP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('37°C', '37°C', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('3', '3', 'CD', 'B-NP', 'O')
('h', 'h', 'NN', 'I-NP', 'O')
('under', 'under', 'IN', 'B-PP', 'O')
('splicing', 'splicing', 'NN', 'B-NP', 'O')
('conditions', 'condition', 'NNS', 'I-NP', 'O')
('(50', '(50', 'CD', 'B-NP', 'O')
('mM', 'mM', 'NN', 'I-NP', 'O')
('HEPES,', 'HEPES,', 'NN', 'I-NP', 'O')
('pH', 'pH', 'NN', 'I-NP', 'O')
('7.0,150', '7.0,150', 'CD', 'I-NP', 'O')
('mM', 'mM', 'NN', 'I-NP', 'O')
('NaCI,', 'NaCI,', 'NN', 'I-NP', 'O')
('5', '5', 'CD', 'I-NP', 'O')
('mM', 'mM', 'NN', 'I-NP', 'O')
('MgCb)', 'MgCb)', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('presence', 'presence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('guanosine', 'guanosine', 'NN', 'B-NP', 'O')
('(200', '(200', 'CD', 'I-NP', 'O')
('pM)', 'pM)', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('100', '100', 'CD', 'B-NP', 'O')
('nM', 'nM', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('in', 'in', 'FW', 'B-ADVP', 'O')
('vitro', 'vitro', 'FW', 'I-ADVP', 'O')
('generated', 'generate', 'VBN', 'B-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'O')
('RNA.', 'RNA.', 'NN', 'I-NP', 'O')
The frans-splicing reaction products were reverse-transcribed at 37°C for 30 min in the presence of argininamide (10 mM) with a 3’ tagged primer that was specific forthe ribozyme’s 3’ exon lacZ sequence (5-ATGTGCTGCAAGGCGATT-3’) (Jones et al.
('The', 'The', 'DT', 'B-NP', 'O')
('frans-splicing', 'frans-splicing', 'JJ', 'I-NP', 'B-protein')
('reaction', 'reaction', 'NN', 'I-NP', 'I-protein')
('products', 'product', 'NNS', 'I-NP', 'I-protein')
('were', 'be', 'VBD', 'B-VP', 'O')
('reverse-transcribed', 'reverse-transcribe', 'VBN', 'I-VP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('37°C', '37°C', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('30', '30', 'CD', 'B-NP', 'O')
('min', 'min', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('presence', 'presence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('argininamide', 'argininamide', 'NN', 'B-NP', 'O')
('(10', '(10', 'CD', 'I-NP', 'O')
('mM)', 'mM)', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('3’', '3’', 'NN', 'I-NP', 'B-DNA')
('tagged', 'tag', 'VBD', 'B-VP', 'I-DNA')
('primer', 'primer', 'NN', 'B-NP', 'I-DNA')
('that', 'that', 'WDT', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('specific', 'specific', 'JJ', 'B-NP', 'O')
('forthe', 'forthe', 'NN', 'I-NP', 'O')
('ribozyme’s', 'ribozyme’', 'NNS', 'I-NP', 'O')
('3’', '3’', 'CD', 'B-NP', 'O')
('exon', 'exon', 'NN', 'I-NP', 'O')
('lacZ', 'lacZ', 'NN', 'I-NP', 'O')
('sequence', 'sequence', 'NN', 'I-NP', 'O')
('(5-ATGTGCTGCAAGGCGATT-3’)', '(5-ATGTGCTGCAAGGCGATT-3’)', 'NN', 'I-NP', 'O')
('(Jones', '(Jone', 'NNS', 'I-NP', 'O')
('et', 'et', 'FW', 'B-ADVP', 'O')
('al.', 'al.', 'FW', 'I-ADVP', 'O')
1996).
('1996).', '1996).', 'LS', 'B-LST', 'O')
Following reverse transcription, the cDNAs were amplified by PCR for 30 cycles using the same 3’ primer and a 5’ primer that was specific for the 5’ end of the target mTERT RNA (5’-GGGGAATTCGTCTAGAG CCACCGTCCA-3’).
('Following', 'Follow', 'VBG', 'B-PP', 'O')
('reverse', 'reverse', 'JJ', 'B-NP', 'O')
('transcription,', 'transcription,', 'NN', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cDNAs', 'cDNA', 'NNS', 'I-NP', 'B-DNA')
('were', 'be', 'VBD', 'B-VP', 'O')
('amplified', 'amplify', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('PCR', 'PCR', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('30', '30', 'CD', 'B-NP', 'O')
('cycles', 'cycle', 'NNS', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('same', 'same', 'JJ', 'I-NP', 'O')
('3’', '3’', 'NN', 'I-NP', 'O')
('primer', 'primer', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('5’', '5’', 'NN', 'I-NP', 'B-DNA')
('primer', 'primer', 'NN', 'I-NP', 'I-DNA')
('that', 'that', 'WDT', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('specific', 'specific', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('5’', '5’', 'NN', 'I-NP', 'O')
('end', 'end', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('(5’-GGGGAATTCGTCTAGAG', '(5’-GGGGAATTCGTCTAGAG', 'NN', 'I-NP', 'O')
('CCACCGTCCA-3’).', 'CCACCGTCCA-3’).', 'NN', 'I-NP', 'O')
The amplified frans-splicing products were then cloned into the pUC19 vector and several cloneswere sequenced.
('The', 'The', 'DT', 'B-NP', 'O')
('amplified', 'amplify', 'VBN', 'I-NP', 'B-protein')
('frans-splicing', 'frans-splicing', 'NN', 'I-NP', 'I-protein')
('products', 'product', 'NNS', 'I-NP', 'I-protein')
('were', 'be', 'VBD', 'B-VP', 'O')
('then', 'then', 'RB', 'I-VP', 'O')
('cloned', 'clone', 'VBN', 'I-VP', 'O')
('into', 'into', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('pUC19', 'pUC19', 'NN', 'I-NP', 'B-cell_line')
('vector', 'vector', 'NN', 'I-NP', 'I-cell_line')
('and', 'and', 'CC', 'O', 'I-cell_line')
('several', 'several', 'JJ', 'B-NP', 'I-cell_line')
('clones', 'clone', 'NNS', 'I-NP', 'I-cell_line')
('were', 'be', 'VBD', 'B-VP', 'O')
('sequenced.', 'sequenced.', 'VBN', 'I-VP', 'O')
Sequence analysis ofthe splicing junction sites revealed that several uridines that were present downstream ofthe AUG start codon (position 30 nt) appeared to be particularly accessible (Fig.
('Sequence', 'Sequence', 'NN', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('ofthe', 'ofthe', 'VBP', 'B-VP', 'O')
('splicing', 'splicing', 'NN', 'B-NP', 'B-DNA')
('junction', 'junction', 'NN', 'I-NP', 'I-DNA')
('sites', 'site', 'NNS', 'I-NP', 'I-DNA')
('revealed', 'reveal', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('several', 'several', 'JJ', 'B-NP', 'O')
('uridines', 'uridine', 'NNS', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('present', 'present', 'JJ', 'B-NP', 'O')
('downstream', 'downstream', 'JJ', 'I-NP', 'O')
('ofthe', 'ofthe', 'NN', 'I-NP', 'O')
('AUG', 'AUG', 'NN', 'I-NP', 'O')
('start', 'start', 'NN', 'I-NP', 'O')
('codon', 'codon', 'NN', 'I-NP', 'O')
('(position', '(position', 'NN', 'I-NP', 'O')
('30', '30', 'CD', 'I-NP', 'O')
('nt)', 'nt)', 'NN', 'I-NP', 'O')
('appeared', 'appear', 'VBD', 'B-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('particularly', 'particularly', 'RB', 'B-ADJP', 'O')
('accessible', 'accessible', 'JJ', 'I-ADJP', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
2).
('2).', '2).', 'LS', 'B-LST', 'O')
The most accessible site was located in the uridines at position 67 on the mTERT RNA.
('The', 'The', 'DT', 'B-NP', 'O')
('most', 'most', 'RBS', 'I-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'O')
('site', 'site', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('located', 'locate', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('uridines', 'uridine', 'NNS', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('position', 'position', 'NN', 'B-NP', 'B-protein')
('67', '67', 'CD', 'I-NP', 'I-protein')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'O')
('RNA.', 'RNA.', 'NN', 'I-NP', 'O')
With the exception of position 67, most of the accessible sites identified using this mapping strategy were generally present in the stem region ofthe RNA’s secondary structure, as predicted by computer modeling (Fig.
('With', 'With', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('exception', 'exception', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('position', 'position', 'NN', 'B-NP', 'B-protein')
('67,', '67,', 'CD', 'I-NP', 'I-protein')
('most', 'most', 'JJS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'B-DNA')
('sites', 'site', 'NNS', 'I-NP', 'I-DNA')
('identified', 'identify', 'VBN', 'B-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('mapping', 'mapping', 'NN', 'I-NP', 'O')
('strategy', 'strategy', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('generally', 'generally', 'RB', 'B-ADJP', 'O')
('present', 'present', 'JJ', 'I-ADJP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('stem', 'stem', 'NN', 'I-NP', 'O')
('region', 'region', 'NN', 'I-NP', 'O')
('ofthe', 'ofthe', 'VBP', 'B-VP', 'O')
('RNA’s', 'RNA’', 'NNS', 'B-NP', 'B-protein')
('secondary', 'secondary', 'JJ', 'B-NP', 'O')
('structure,', 'structure,', 'NN', 'I-NP', 'O')
('as', 'as', 'IN', 'B-SBAR', 'O')
('predicted', 'predict', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('computer', 'computer', 'NN', 'B-NP', 'O')
('modeling', 'modeling', 'NN', 'I-NP', 'O')
('(Fig.', '(Fig.', 'NN', 'I-NP', 'O')
2).
('2).', '2).', 'LS', 'B-LST', 'O')
The relative frans-splicing efficiency at several sites on the target RNA in cells and in vitro has previously been shown to be closely correlated with the predicted accessibility determined by mapping studies (Ryu et al., 2003; Kwon et al., 2005).
('The', 'The', 'DT', 'B-NP', 'O')
('relative', 'relative', 'JJ', 'I-NP', 'O')
('frans-splicing', 'frans-splicing', 'NN', 'I-NP', 'O')
('efficiency', 'efficiency', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('several', 'several', 'JJ', 'B-NP', 'O')
('sites', 'site', 'NNS', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('cells', 'cell', 'NNS', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('in', 'in', 'FW', 'B-PP', 'O')
('vitro', 'vitro', 'FW', 'B-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('previously', 'previously', 'RB', 'I-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('closely', 'closely', 'RB', 'I-VP', 'O')
('correlated', 'correlate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('predicted', 'predict', 'VBN', 'I-NP', 'O')
('accessibility', 'accessibility', 'NN', 'I-NP', 'O')
('determined', 'determine', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('mapping', 'map', 'VBG', 'B-VP', 'O')
('studies', 'study', 'NNS', 'B-NP', 'O')
('(Ryu', '(Ryu', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2003;', '2003;', ':', 'O', 'O')
('Kwon', 'Kwon', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
Therefore, we cannot anticipate ribozyme-accessible sites on the substrate solely by using the computer-predicted RNA structure.
('Therefore,', 'Therefore,', 'IN', 'B-SBAR', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('cannot', 'cannot', 'MD', 'B-VP', 'O')
('anticipate', 'anticipate', 'VB', 'I-VP', 'O')
('ribozyme-accessible', 'ribozyme-accessible', 'JJ', 'B-NP', 'B-DNA')
('sites', 'site', 'NNS', 'I-NP', 'I-DNA')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('substrate', 'substrate', 'NN', 'I-NP', 'O')
('solely', 'solely', 'RB', 'B-ADVP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('computer-predicted', 'computer-predicted', 'JJ', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('structure.', 'structure.', 'NN', 'I-NP', 'O')
A specific ribozyme targeting position 67 on the mTERT RNA (Rib67) was constructed by in vitro transcription of cDNA template.
('A', 'A', 'DT', 'B-NP', 'O')
('specific', 'specific', 'JJ', 'I-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('targeting', 'target', 'VBG', 'B-VP', 'O')
('position', 'position', 'NN', 'B-NP', 'B-protein')
('67', '67', 'CD', 'I-NP', 'I-protein')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('(Rib67)', '(Rib67)', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('constructed', 'construct', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('in', 'in', 'FW', 'B-NP', 'O')
('vitro', 'vitro', 'FW', 'I-NP', 'O')
('transcription', 'transcription', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('cDNA', 'cDNA', 'NN', 'B-NP', 'B-DNA')
('template.', 'template.', 'NN', 'I-NP', 'O')
The pT7L-21 plasmid, which encodes a slightly shortened version ofthe natural group I intron from Tetrahymena, was used to create the template by PCR.
('The', 'The', 'DT', 'B-NP', 'O')
('pT7L-21', 'pT7L-21', 'NN', 'I-NP', 'O')
('plasmid,', 'plasmid,', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('encodes', 'encode', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('slightly', 'slightly', 'RB', 'I-NP', 'O')
('shortened', 'shorten', 'VBN', 'I-NP', 'O')
('version', 'version', 'NN', 'I-NP', 'B-DNA')
('ofthe', 'ofthe', 'DT', 'B-NP', 'I-DNA')
('natural', 'natural', 'JJ', 'I-NP', 'I-DNA')
('group', 'group', 'NN', 'I-NP', 'I-DNA')
('I', 'I', 'CD', 'I-NP', 'I-DNA')
('intron', 'intron', 'NN', 'I-NP', 'I-DNA')
('from', 'from', 'IN', 'B-PP', 'O')
('Tetrahymena,', 'Tetrahymena,', 'NN', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('create', 'create', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('template', 'template', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('PCR.', 'PCR.', 'NN', 'B-NP', 'O')
The 5’ primer contained the T7 promoter and the ribozyme’s IGS, while the 3’ primer was specific forthe 3’ exon sequence (Sullengerand Cech, 1994; Jones et al.,1996).
('The', 'The', 'DT', 'B-NP', 'O')
('5’', '5’', 'NN', 'I-NP', 'O')
('primer', 'primer', 'NN', 'I-NP', 'O')
('contained', 'contain', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('T7', 'T7', 'NN', 'I-NP', 'B-DNA')
('promoter', 'promoter', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ribozyme’s', 'ribozyme’', 'NNS', 'I-NP', 'O')
('IGS,', 'IGS,', 'NN', 'I-NP', 'B-protein')
('while', 'while', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('3’', '3’', 'NN', 'I-NP', 'B-DNA')
('primer', 'primer', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'I-DNA')
('specific', 'specific', 'JJ', 'B-NP', 'I-DNA')
('forthe', 'forthe', 'NN', 'I-NP', 'I-DNA')
('3’', '3’', 'NN', 'I-NP', 'I-DNA')
('exon', 'exon', 'NN', 'I-NP', 'I-DNA')
('sequence', 'sequence', 'NN', 'I-NP', 'I-DNA')
('(Sullengerand', '(Sullengerand', 'NNP', 'I-NP', 'O')
('Cech,', 'Cech,', 'NNP', 'I-NP', 'O')
('1994;', '1994;', 'CD', 'I-NP', 'O')
('Jones', 'Jones', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1996).', '1996).', 'CD', 'B-NP', 'O')
The IGS on the L-21 frans-sphcing ribozyme (5-GGAGGG-3') was exchanged with 5'-GGAGAG-3' in Rib67 and the specific ribozyme (100 nM) was then incubated with the substrate mTERT RNA (10 nM) under splicing conditions.
('The', 'The', 'DT', 'B-NP', 'O')
('IGS', 'IGS', 'NN', 'I-NP', 'B-protein')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('L-21', 'L-21', 'NN', 'I-NP', 'B-protein')
('frans-sphcing', 'frans-sphcing', 'JJ', 'I-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
("(5-GGAGGG-3')", "(5-GGAGGG-3')", 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('exchanged', 'exchange', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
("5'-GGAGAG-3'", "5'-GGAGAG-3'", 'NN', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Rib67', 'Rib67', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('specific', 'specific', 'JJ', 'I-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('(100', '(100', 'CD', 'I-NP', 'O')
('nM)', 'nM)', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('then', 'then', 'RB', 'I-VP', 'O')
('incubated', 'incubate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('substrate', 'substrate', 'NN', 'I-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('(10', '(10', 'CD', 'I-NP', 'O')
('nM)', 'nM)', 'NN', 'I-NP', 'O')
('under', 'under', 'IN', 'B-PP', 'O')
('splicing', 'splicing', 'NN', 'B-NP', 'O')
('conditions.', 'conditions.', 'NN', 'I-NP', 'O')
RT-PCR analyses were performed using a 3' primer specific for the 3' exon tag sequence and a 5' primer specific for mTERT RNA.
('RT-PCR', 'RT-PCR', 'NN', 'B-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('performed', 'perform', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
("3'", "3'", 'JJ', 'I-NP', 'B-DNA')
('primer', 'primer', 'NN', 'I-NP', 'I-DNA')
('specific', 'specific', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
("3'", "3'", 'JJ', 'I-NP', 'B-DNA')
('exon', 'exon', 'NN', 'I-NP', 'I-DNA')
('tag', 'tag', 'NN', 'I-NP', 'I-DNA')
('sequence', 'sequence', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
("5'", "5'", 'JJ', 'I-NP', 'B-DNA')
('primer', 'primer', 'NN', 'I-NP', 'I-DNA')
('specific', 'specific', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mTERT', 'mTERT', 'NN', 'B-NP', 'O')
('RNA.', 'RNA.', 'NN', 'I-NP', 'O')
The amplified fragment corresponded to the expected size of 165 bp using the mTERT RNA and Rib67 (data not shown).
('The', 'The', 'DT', 'B-NP', 'O')
('amplified', 'amplify', 'VBN', 'I-NP', 'O')
('fragment', 'fragment', 'NN', 'I-NP', 'O')
('corresponded', 'correspond', 'VBD', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('expected', 'expect', 'VBN', 'I-NP', 'O')
('size', 'size', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('165', '165', 'CD', 'B-NP', 'O')
('bp', 'bp', 'NN', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Rib67', 'Rib67', 'NN', 'I-NP', 'O')
('(data', '(data', 'NNS', 'I-NP', 'O')
('not', 'not', 'RB', 'O', 'O')
('shown).', 'shown).', 'VB', 'B-VP', 'O')
Sequence analyses of the amplified spliced products demonstrated that Rib67 correctly trans-spliced its 3' exon tag onto the mTERT target RNA at the predicted reaction site (Fig.
('Sequence', 'Sequence', 'NN', 'B-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('amplified', 'amplify', 'VBN', 'I-NP', 'B-protein')
('spliced', 'splice', 'VBN', 'I-NP', 'I-protein')
('products', 'product', 'NNS', 'I-NP', 'I-protein')
('demonstrated', 'demonstrate', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('Rib67', 'Rib67', 'NN', 'B-NP', 'B-protein')
('correctly', 'correctly', 'RB', 'B-ADVP', 'O')
('trans-spliced', 'trans-splice', 'VBD', 'B-VP', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
("3'", "3'", 'JJ', 'I-NP', 'B-DNA')
('exon', 'exon', 'NN', 'I-NP', 'I-DNA')
('tag', 'tag', 'NN', 'I-NP', 'I-DNA')
('onto', 'onto', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTERT', 'mTERT', 'NN', 'I-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('predicted', 'predict', 'VBN', 'I-NP', 'O')
('reaction', 'reaction', 'NN', 'I-NP', 'O')
('site', 'site', 'NN', 'I-NP', 'O')
('(Fig.', '(Fig.', 'NN', 'I-NP', 'O')
3).
('3).', '3).', 'LS', 'B-LST', 'O')
From these results we conclude that specific ribozyme targeting of predicted accessible sites can replace mTERT RNA with a 3' exon tagged at the 3' end of the ribozyme with high reliability by using targeted trans-splidng.
('From', 'From', 'IN', 'B-PP', 'O')
('these', 'these', 'DT', 'B-NP', 'O')
('results', 'result', 'NNS', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('conclude', 'conclude', 'VBP', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('specific', 'specific', 'JJ', 'B-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'O')
('targeting', 'targeting', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('predicted', 'predict', 'VBN', 'B-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'O')
('sites', 'site', 'NNS', 'I-NP', 'O')
('can', 'can', 'MD', 'B-VP', 'O')
('replace', 'replace', 'VB', 'I-VP', 'O')
('mTERT', 'mTERT', 'NN', 'B-NP', 'B-RNA')
('RNA', 'RNA', 'NN', 'I-NP', 'I-RNA')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
("3'", "3'", 'JJ', 'I-NP', 'B-DNA')
('exon', 'exon', 'NN', 'I-NP', 'I-DNA')
('tagged', 'tag', 'VBN', 'B-VP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
("3'", "3'", 'JJ', 'I-NP', 'B-DNA')
('end', 'end', 'NN', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'B-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('high', 'high', 'JJ', 'B-NP', 'O')
('reliability', 'reliability', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('targeted', 'target', 'VBN', 'B-VP', 'O')
('trans-splidng.', 'trans-splidng.', 'JJ', 'B-ADJP', 'O')
This mTERT-specific ribozyme will be useful for validation of RNA replacement as an approach to cancer gene therapy in syngeneic mouse models.
('This', 'This', 'DT', 'B-NP', 'O')
('mTERT-specific', 'mTERT-specific', 'JJ', 'I-NP', 'B-protein')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'I-protein')
('will', 'will', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('useful', 'useful', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('validation', 'validation', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('RNA', 'RNA', 'NN', 'B-NP', 'O')
('replacement', 'replacement', 'NN', 'I-NP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('approach', 'approach', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('cancer', 'cancer', 'NN', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('therapy', 'therapy', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('syngeneic', 'syngeneic', 'JJ', 'B-NP', 'O')
('mouse', 'mouse', 'NN', 'I-NP', 'O')
('models.', 'models.', 'NN', 'I-NP', 'O')
There are major differences in the dynamics and regulation of telomerase in mouse and human cells.
('There', 'There', 'EX', 'B-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('major', 'major', 'JJ', 'B-NP', 'O')
('differences', 'difference', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('dynamics', 'dynamic', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('regulation', 'regulation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('telomerase', 'telomerase', 'NN', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('mouse', 'mouse', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('human', 'human', 'JJ', 'B-NP', 'O')
('cells.', 'cells.', 'NNS', 'I-NP', 'O')
For example, the telomeres of laboratory mice are significantly longer (40-60 kb) than those in human (10 kb), and telomerase is widely expressed in adult mouse tissues (Newbold, 1997; Greeberg et al., 1998).
('For', 'For', 'IN', 'B-PP', 'O')
('example,', 'example,', 'NN', 'B-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('telomeres', 'telomere', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('laboratory', 'laboratory', 'NN', 'B-NP', 'O')
('mice', 'mouse', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('significantly', 'significantly', 'RB', 'B-NP', 'O')
('longer', 'long', 'JJR', 'I-NP', 'O')
('(40-60', '(40-60', 'CD', 'I-NP', 'O')
('kb)', 'kb)', 'NN', 'I-NP', 'O')
('than', 'than', 'IN', 'B-PP', 'O')
('those', 'those', 'DT', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'O')
('(10', '(10', 'CD', 'I-NP', 'O')
('kb),', 'kb),', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('telomerase', 'telomerase', 'NN', 'I-NP', 'B-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('widely', 'widely', 'RB', 'I-VP', 'O')
('expressed', 'express', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('adult', 'adult', 'JJ', 'B-NP', 'O')
('mouse', 'mouse', 'NN', 'I-NP', 'O')
('tissues', 'tissue', 'NNS', 'I-NP', 'O')
('(Newbold,', '(Newbold,', 'NNP', 'B-NP', 'O')
('1997;', '1997;', 'CD', 'I-NP', 'O')
('Greeberg', 'Greeberg', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1998).', '1998).', 'CD', 'B-NP', 'O')
The use of inhibitors such as trans-cleavage ribozymes, antisense oligonucleotides and siRNA to repress mouse telomerase expression may be limited in their use with mouse tumors.
('The', 'The', 'DT', 'B-NP', 'O')
('use', 'use', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('inhibitors', 'inhibitor', 'NNS', 'B-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('trans-cleavage', 'trans-cleavage', 'JJ', 'B-NP', 'O')
('ribozymes,', 'ribozymes,', 'NN', 'I-NP', 'O')
('antisense', 'antisense', 'JJ', 'I-NP', 'O')
('oligonucleotides', 'oligonucleotide', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('siRNA', 'siRNA', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('repress', 'repress', 'VB', 'I-VP', 'O')
('mouse', 'mouse', 'NN', 'B-NP', 'B-protein')
('telomerase', 'telomerase', 'NN', 'I-NP', 'I-protein')
('expression', 'expression', 'NN', 'I-NP', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('limited', 'limit', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('use', 'use', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('mouse', 'mouse', 'NN', 'B-NP', 'O')
('tumors.', 'tumors.', 'NNS', 'I-NP', 'O')
This is due to the lag phase that occurs between the time of telomerase inhibition and the time at which the telomeres actually become short enough to cause harmful effects associated with cancer growth.
('This', 'This', 'DT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('due', 'due', 'IN', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('lag', 'lag', 'NN', 'I-NP', 'O')
('phase', 'phase', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('occurs', 'occur', 'VBZ', 'B-VP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('time', 'time', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('telomerase', 'telomerase', 'NN', 'B-NP', 'O')
('inhibition', 'inhibition', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('time', 'time', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('the', 'the', 'DT', 'O', 'O')
('telomeres', 'telomere', 'VBZ', 'B-VP', 'O')
('actually', 'actually', 'RB', 'I-VP', 'O')
('become', 'become', 'VBN', 'I-VP', 'O')
('short', 'short', 'JJ', 'B-ADJP', 'O')
('enough', 'enough', 'RB', 'I-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('cause', 'cause', 'VB', 'I-VP', 'O')
('harmful', 'harmful', 'JJ', 'B-NP', 'O')
('effects', 'effect', 'NNS', 'I-NP', 'O')
('associated', 'associate', 'VBN', 'B-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('cancer', 'cancer', 'NN', 'B-NP', 'O')
('growth.', 'growth.', 'NN', 'I-NP', 'O')
However, the trans­ splicing approach will overcome the lag phase because it can reduce the TERT level and can simultaneously induce cytotoxicity in the TERT-expressing cancer cells.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('trans\xad', 'trans\xad', 'NN', 'I-NP', 'O')
('splicing', 'splicing', 'NN', 'I-NP', 'O')
('approach', 'approach', 'NN', 'I-NP', 'O')
('will', 'will', 'MD', 'B-VP', 'O')
('overcome', 'overcome', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('lag', 'lag', 'NN', 'I-NP', 'O')
('phase', 'phase', 'NN', 'I-NP', 'O')
('because', 'because', 'IN', 'B-SBAR', 'O')
('it', 'it', 'PRP', 'B-NP', 'O')
('can', 'can', 'MD', 'B-VP', 'O')
('reduce', 'reduce', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('TERT', 'TERT', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('can', 'can', 'MD', 'B-VP', 'O')
('simultaneously', 'simultaneously', 'RB', 'I-VP', 'O')
('induce', 'induce', 'VB', 'I-VP', 'O')
('cytotoxicity', 'cytotoxicity', 'NN', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('TERT-expressing', 'TERT-expressing', 'JJ', 'I-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('cells.', 'cells.', 'NNS', 'I-NP', 'O')
Moreover, cancer- or condition-specific expression of the mTERT-targeting ribozyme could improve the specificity of tumor cytotoxicity (Song and Lee, 2006).
('Moreover,', 'Moreover,', 'JJR', 'B-NP', 'O')
('cancer-', 'cancer-', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('condition-specific', 'condition-specific', 'JJ', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTERT-targeting', 'mTERT-targeting', 'NN', 'I-NP', 'B-protein')
('ribozyme', 'ribozyme', 'NN', 'I-NP', 'I-protein')
('could', 'could', 'MD', 'B-VP', 'O')
('improve', 'improve', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('specificity', 'specificity', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('tumor', 'tumor', 'NN', 'B-NP', 'O')
('cytotoxicity', 'cytotoxicity', 'NN', 'I-NP', 'O')
('(Song', '(Song', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Lee,', 'Lee,', 'NNP', 'B-NP', 'O')
('2006).', '2006).', 'CD', 'I-NP', 'O')
Recently, many gene therapy protocols based on inhibitory RNA or short oligonucleotides have been described.
('Recently,', 'Recently,', 'NN', 'B-NP', 'O')
('many', 'many', 'JJ', 'I-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('therapy', 'therapy', 'NN', 'I-NP', 'O')
('protocols', 'protocol', 'NNS', 'I-NP', 'O')
('based', 'base', 'VBN', 'B-PP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('inhibitory', 'inhibitory', 'JJ', 'B-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('short', 'short', 'JJ', 'B-NP', 'O')
('oligonucleotides', 'oligonucleotide', 'NNS', 'I-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('described.', 'described.', 'VBN', 'I-VP', 'O')
A key factor that influences the efficiency of RNA-mediated cancer suppression is the accessibility of the substrate RNA for binding of inhibitory elements.
('A', 'A', 'DT', 'B-NP', 'O')
('key', 'key', 'JJ', 'I-NP', 'O')
('factor', 'factor', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('influences', 'influence', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('efficiency', 'efficiency', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('RNA-mediated', 'RNA-mediated', 'JJ', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('suppression', 'suppression', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('accessibility', 'accessibility', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('substrate', 'substrate', 'NN', 'I-NP', 'O')
('RNA', 'RNA', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('binding', 'binding', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('inhibitory', 'inhibitory', 'JJ', 'B-NP', 'O')
('elements.', 'elements.', 'NNS', 'I-NP', 'O')
Mapping studies, such as those described here, could be used generally in a wide range of applications for optimizing intracellular anti-TERT activity with various inhibitory RNAs.
('Mapping', 'Map', 'VBG', 'B-VP', 'O')
('studies,', 'studies,', 'NN', 'B-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('those', 'those', 'DT', 'B-NP', 'O')
('described', 'describe', 'VBN', 'I-NP', 'O')
('here,', 'here,', 'NN', 'I-NP', 'O')
('could', 'could', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('generally', 'generally', 'RB', 'B-ADVP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('wide', 'wide', 'JJ', 'I-NP', 'O')
('range', 'range', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('applications', 'application', 'NNS', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('optimizing', 'optimize', 'VBG', 'B-VP', 'O')
('intracellular', 'intracellular', 'JJ', 'B-NP', 'O')
('anti-TERT', 'anti-TERT', 'JJ', 'I-NP', 'O')
('activity', 'activity', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('inhibitory', 'inhibitory', 'JJ', 'I-NP', 'O')
('RNAs.', 'RNAs.', 'NN', 'I-NP', 'O')
Furthermore, the mapping methodology that was developed in this study could potentially be used to identify the most accessible sites in other unique tumor-associated RNAs or viral RNAs for the development of therapeutic strategies for treating malignant or infectious diseases.
('Furthermore,', 'Furthermore,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mapping', 'mapping', 'NN', 'I-NP', 'O')
('methodology', 'methodology', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('developed', 'develop', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('could', 'could', 'MD', 'B-VP', 'O')
('potentially', 'potentially', 'RB', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('most', 'most', 'RBS', 'I-NP', 'O')
('accessible', 'accessible', 'JJ', 'I-NP', 'O')
('sites', 'site', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('unique', 'unique', 'JJ', 'I-NP', 'B-RNA')
('tumor-associated', 'tumor-associated', 'JJ', 'I-NP', 'I-RNA')
('RNAs', 'RNA', 'NNS', 'I-NP', 'I-RNA')
('or', 'or', 'CC', 'O', 'O')
('viral', 'viral', 'JJ', 'B-NP', 'B-RNA')
('RNAs', 'RNA', 'NNS', 'I-NP', 'I-RNA')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('development', 'development', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('therapeutic', 'therapeutic', 'JJ', 'B-NP', 'O')
('strategies', 'strategy', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('treating', 'treat', 'VBG', 'B-VP', 'O')
('malignant', 'malignant', 'JJ', 'B-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('infectious', 'infectious', 'JJ', 'I-NP', 'O')
('diseases.', 'diseases.', 'NNS', 'I-NP', 'O')
